Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
was downgraded from Buy to Neutral at Miller Tabak. $38 price target. Company is spending more to generate future growth.
was downgraded to Equal Weight from Overweight at Barclays. Solid third-quarter results, but valuation full, Barclays said. Price target raised to $17 from $14.
was downgraded from Outperform to Market Perform at BMO Capital Markets. Valuation call, based on a $26 price target.
was initiated with an Overweight rating and $68 price target at Barclays. Anchored by a strong U.S. business, UGG has significant growth potential globally, Barclays said.
was downgraded to Market Perform at BMO Capital. $16 price target. Company continues to be hurt by lower natural gas prices.
Goodrich Petroleum was upgraded from Hold to Buy at Stifel Nicolaus. $17 price target. Company is seeing higher potential growth from some of its properties.
was upgraded to Buy from Underperform at Bank of America/Merrill Lynch on improving Consta outlook. Price target increased to $15 from $13.
Apollo Commercial Real Estate
was initiated at Bank of America/Merrill Lynch with a Buy rating and an $18 price target. Over the next 12 months ARI will optimize its investment portfolio and generate returns in the 9%-10% ROE range, Bank of America/Merrill Lynch said.
was downgraded from Buy to Hold at ThinkEquity. $30 price target. Company is seeing lower sales.
Coeur d'Alene Mines
was upgraded at RBC Capital from Underperform to Sector Perform. $27 price target. Company is delivering more consistent growth.
was downgraded at RBC Capital from Outperform to Sector Perform. $7 price target. Growth visibility is declining.
was downgraded to Neutral from Buy at Bank of America/Merrill Lynch. High single-digit supply growth by the Canadian carriers will be more difficult to absorb in the seasonally slow fall and winter seasons, Bank of America/Merrill Lynch said.
was upgraded from Hold to Buy at ThinkEquity. $32 price target. Stock looks attractive following a 5% pullback.
was downgraded at Credit Suisse to Underperform from Neutral as possible catalysts are starting to fade. Price target reduced to $21 from $28.
( HOC) downgraded at Bank of America/Merrill Lynch to Neutral from Buy. Valuation call, Bank of America/Merrill Lynch said. $35 price target maintained.
upgraded at Citigroup from Sell to Hold. $28 price target. Estimates also boosted, to match the company's new guidance.
was downgraded to Equal-weight at Morgan Stanley. Company is seeing higher price competition.
was upgraded at Morgan Keegan from Market Perform to Outperform. Valuation call, as earnings growth should accelerate in 2011. Company is also likely to pay down debt.
was downgraded at Duncan Williams from Strong Buy to Buy. Valuation call, based on a $35 price target.
was downgraded at Goldman Sachs from Buy to Neutral. Company was also removed from the Conviction List, as it is the most sensitive in the group to interest rates. $52 price target.
was upgraded at Oppenheimer from Perform to Outperform. $15 price target. Company is growing its niche and moving into its strongest period of the year.
RF Micro Devices
was downgraded at Davenport from Strong Buy to Neutral. Valuation call, as the stock is up 58% year-to-date.
was upgraded at Goldman Sachs from Neutral to Buy. New analyst likes the company's global exposure and excess capital. $50 price target.
was initiated at Credit Suisse with a Neutral rating and $21 price target as there's more risk in wine than beer. There are better opportunities in the segment, Credit Suisse said.
( SUG) was downgraded at Wells Fargo from Outperform to Market Perform. Company faces challenges in its midstream business.
( TBL) was upgraded at Citigroup from Sell to Hold. $25 price target. Company is improving its gross margin.
Two Harbors Investment
was initiated at Barclays with an Overweight rating and $10 price target. Hybrid model gives flexibility to optimize returns, Barclays said.
( WJA) was downgraded at Bank of America/Merrill Lynch to Underperform from Neutral as near term expectations are too high. Maintain $13 price target.
was upgraded at UBS from Neutral to Buy. $59 price target. Estimates also boosted, given higher expectations for Concerta.
This article was written by a staff member of TheStreet.